Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

AI Models May Serve As Additional Genetic Counseling Resource in Gynecologic Oncology

March 18th 2024

ChatGPT may provide comprehensive and correct answers to genetic counseling questions for patients with gynecologic cancers.

Disparities in Care Outcomes Persist Between Black and White Patients With Endometrioid Endometrial Carcinoma

March 18th 2024

Black patients with endometrioid endometrial carcinoma experienced an increased risk of death and lower enrollment in clinical trials vs White patients.

Dr Randall on PROs With Pembrolizumab Plus Chemoradiotherapy in Cervical Cancer

March 17th 2024

Leslie M. Randall, MD, MAS, discusses patient-reported outcomes from the ENGOT-cx11/GOG 3047/KEYNOTE-A18 trial in locally advanced cervical cancer.

Nab-Sirolimus Elicits Responses in Gynecologic/Peritoneal PEComa

March 17th 2024

Patients with perivascular epithelioid sarcoma of gynecologic or peritoneal origin experienced durable responses when treated with nab-sirolimus.

Study Evaluates Synergistic Potential of Nab-Sirolimus Plus Letrozole in Advanced/Recurrent Endometrial Cancer

March 17th 2024

The activity of nab-sirolimus plus letrozole is under study in patients with advanced or recurrent endometrioid endometrial cancer.

Dr Nasioudis on the Use of SLNB in Metastatic Vulvar Squamous Cell Carcinoma

March 16th 2024

Dimitrios Nasioudis, MD, discusses outcomes of patients with metastatic vulvar squamous cell carcinoma who underwent sentinel lymph node biopsy.

Tislelizumab Plus Chemo Generates Responses in Locally Advanced Cervical Cancer

March 16th 2024

Neoadjuvant tislelizumab in combination with chemotherapy was safe and produced responses in patients with locally advanced cervical cancer.

Dostarlimab Plus Chemo Demonstrates Survival Advantage in Advanced Endometrial Cancer

March 16th 2024

Dostarlimab plus carboplatin/paclitaxel improved overall survival vs placebo plus chemotherapy in primary advanced or recurrent endometrial cancer.

Pembrolizumab Plus Chemo Generates Favorable OS Trend in Endometrial Cancer

March 16th 2024

The addition of pembrolizumab to chemotherapy led to a favorable overall survival benefit vs chemotherapy plus placebo in endometrial cancer.

Social Determinants of Health Linked With Varying Cervical Cancer Rates in the US

March 16th 2024

Social determinants of health were associated with geographical variations in the rates of cervical cancer in the United States.

Pembrolizumab Plus Concurrent CRT Meets OS End Point in High-Risk, Locally Advanced Cervical Cancer

March 15th 2024

The KEYNOTE-A18 trial met its coprimary end point of improved OS with pembrolizumab plus concurrent chemoradiotherapy in high-risk cervical cancer.

Dr Franco on the Integration of Immunotherapy Treatment in Endometrial Cancer

March 14th 2024

Idalid Franco, MD, MPH, discusses the use of radiation therapy and immunomodulatory agents in the treatment of endometrial cancer.

Modesitt Spotlights the Latest ADC Breakthroughs in Gynecologic Oncology

March 11th 2024

Susan C. Modesitt, MD, FACOG, FACS, sheds light on the latest research with antibody-drug conjugates across gynecologic cancers.

Dr Miller on the Importance of Patient Advocacy in Gynecologic Oncology

March 8th 2024

Eirwen M. Miller, MD, discusses the importance of advocating for women in gynecologic oncology on International Women’s Day.

Empowering Women in Oncology and Beyond on International Women’s Day

March 8th 2024

Eirwen M. Miller, MD, discusses her experience in the oncology field and the importance of ensuring gender is not a defining quality for oncologists.

ABSK061 Demonstrates Safety, Preliminary Efficacy in FGFR2/3+ Advanced Solid Tumors

March 7th 2024

ABSK061 was well tolerated and elicited responses in patients with advanced solid tumors harboring FGFR2/3 alterations.

Modesitt Reflects on the Art of Treatment Selection Amidst Expansion of Targeted and Immunotherapies in Gynecologic Oncology

March 6th 2024

NICE Recommends Dostarlimab Plus Chemo in MSI-High/dMMR Endometrial Cancer

March 5th 2024

The National Institute for Health and Care Excellence recommends the approval of dostarlimab plus chemotherapy for advanced/recurrent endometrial cancer.

Discordant dMMR/IHC Status Correlates With Improved Treatment Outcomes in CRC and Endometrial Cancer

February 27th 2024

Patients with mismatch repair–deficient, immunohistochemistry-intact colorectal cancer or endometrial cancer benefit from immune checkpoint inhibitors.

Revisit Every OncLive On Air Episode From January 2024

February 26th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.